Transcription factors bind to a specific DNA sequence and regulate important metabolic functions such as cell growth, development and differentiation. There is great interest in understanding the function of these regulatory proteins, especially when their role is linked to oncogenesis. The PU.1 transcription factor is a member of the ets gene family that have been implicated in the development of erythroid leukemia and tumorigenesis in breast cancers. The ets proteins share a conserved region of 85 amino acids (the ETS domain) that binds DNA and recognizes a purine-rich sequence with the core sequence: 5'-GGAA/T-3'. This domain represents a new, yet uncharacterized DNA-binding motif, with no homology to other DNA-binding structures. The PU.1 domain has been crystallized in complex with DNA and high resolution x-ray diffraction data have been collected. In this project, iodinated DNA and heavy metal-substituted protein will be used to solve the crystallographic phases of the complex by multiple isomorphous replacement methods. Atomic models will be used to understand the molecular basis for the function of ets-related transcription factors and to evaluate their role in the development of cancer. The experience gained from the DNA-binding domain will be used to express and purify full-length PU.1 protein for crystallization and structure analysis. This structure will reveal the structure-function relationship of the activation domain to the DNA-binding domain.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32CA066244-03
Application #
2458160
Study Section
Special Emphasis Panel (ZRG3-BBCB (01))
Project Start
1997-08-01
Project End
Budget Start
1997-08-01
Budget End
1998-04-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Savarese, Diane M F; Savy, Gayle; Vahdat, Linda et al. (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29:501-13
Vahdat, L T; Balmaceda, C; Papadopoulos, K et al. (2002) Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant 30:149-55
Vahdat, L; Papadopoulos, K; Lange, D et al. (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-7
Antman, K; Chang, Y (2000) Kaposi's sarcoma. N Engl J Med 342:1027-38
Antman, K; Shea, S (1999) Screening mammography under age 50. JAMA 281:1470-2
Vahdat, L T; Papadopoulos, K; Balmaceda, C et al. (1998) Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res 4:1689-95
Hesdorffer, C; Ayello, J; Ward, M et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 16:165-72
Vahdat, L; Antman, K (1997) High-dose chemotherapy with autologous stem cell support for breast cancer. Curr Opin Hematol 4:381-9
Papadopoulos, K P; Ayello, J; Tugulea, S et al. (1997) Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61-8
Gammon, M D; Wolff, M S; Neugut, A I et al. (1997) Temporal variation in chlorinated hydrocarbons in healthy women. Cancer Epidemiol Biomarkers Prev 6:327-32

Showing the most recent 10 out of 12 publications